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Abstract  
Introduction: Reports of increasing resistance of uropathogens to antimicrobials is of global concern. Culture and drug susceptibility tests remain 
a vital guide to effective therapy. The aim of this study was to determine the susceptibility pattern of isolated uropathogens to ciprofloxacin at the 
Ghana Police Hospital. Methods: A total of 705 mid-stream urine samples were collected from patients suspected of having urinary tract infection, 
and visited the Ghana Police Hospital's laboratory from December 2013 to March 2014. Samples were cultured and isolates identified by standard 
methods, after which isolates susceptibility to ciprofloxacin was determined. Results: Prevalence of urinary tract infection among patients' whose 
samples were analyzed was 15.9%. Predominant uropathogens isolated were E .coli (46.4%), Coliform (41.1%) and Coliform spp. 
with Candida (6.2%). Other isolates were Pseudomonas spp. (2.7%), Salmonella spp. (1.8%), Candida spp. (0.9%) and Klebsiella spp (0.9%). The 
overall resistance among the top three isolated uropathogens to ciprofloxacin was 35.9%. Resistance pattern demonstrated by respective isolates 
to ciprofloxacin were: E. coli (38.5%), Coliform (54.3%), and Coliform spp. with Candida (15%). The other isolates showed 100% sensitivity. 
Conclusion: This study revealed a relatively high ciprofloxacin resistance among isolated uropathogens, hence, the need for prudent prescribing 
and use of ciprofloxacin in urinary tract infection management. 
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Introduction 
 
Urinary tract infections (UTIs) are common among inpatients and 
outpatients, ranking second only to respiratory infections [1]. 
Worldwide, Escherichia coli (E. coli) andStaphylococcus 
saprophyticus are among the predominant isolates of UTIs [2]. 
Other bacterial isolates found in Sub-Saharan Africa 
include Klebsiella pneumonia, Proteus mirabilis, Staphylococcus 
aureus, Pseudomas aeruginosa and Enteroeaseus feacalis [3-5]. 
Increasing microbial resistance to conventional antibiotics like beta-
lactams, aminoglcosides, sulfonamides and cephalosporins used in 
UTI management necessitated the use of other agents such as 
macrolides and fluoroquinolones. 
  
Since their introduction, fluoroquinolones have become a mainstay 
in the treatment of bacterial infections [6, 7]. Fluoroquinolones are 
often preferred as first line agents in the management of UTIs, 
especially when antimicrobial resistance is of concern [8, 9]. They 
are also recommended where conventional agents are less desirable 
due to toxicity or hypersensitivity concerns [10]. Ciprofloxacin is the 
most frequently prescribed fluoroquinolone for UTIs because of its 
availability in oral and intravenous formulations, favorable 
bioavailability, and pharmacokinetics which allows twice-daily 
administration [11,12]. Resistance to fluoroquinolones has increased 
markedly since their introduction for treatment of UTI. 
Rattanaumpawan et al, documented fluoroquinolone resistance of 
15.8% and 57.4% among E. coli and A. baumannii respectively 
[13]. In Africa, substandard drugs, indiscriminate use of antibiotics 
and erratic prescription by unqualified drug sellers have been 
identified as contributing to emergence of resistance [14]. Evidence 
of increasing resistance to ciprofloxacin in some communities is also 
documented [15, 16]. A recent antimicrobial susceptibility study of 
isolated uropathogens at the Ghana Police Hospital revealed high 
resistance to conventional antibiotics [17]. Changes in drug 
resistance pattern among uropathogens have led to reassessment of 
local antimicrobial agents [18]. Currently, very little data is available 
on the susceptibility pattern of uropathogens to ciprofloxacin in 
Ghana, although the drug is recommended in the national treatment 
guidelines for UTI management. The aim of this study was to 
determine the susceptibility pattern of recently isolated 








This was a cross-sectional study that involved analyzing 705 urine 
samples of suspected UTI patients, who visited the Ghana Police 
Hospital's laboratory from December 2013 to March 2014. The 
population consisted of both in- and out-patients. 
  
Sample collection and processing 
  
Midstream urine samples were collected in sterile urine containers. 
With a calibrated wire, a loop-full (0.01 ml) of urine was inoculated 
onto a quarter-plate of Cysteine Lactose Electrolyte-Deficient agar 
(CLED) (Biotic Laboratories Ltd, U.K) and incubated at 37°C for 24 
hours in Nodermann GMBH incubator (Germany). After incubation 
period, colonies were enumerated and those with significant growth 
identified. Significant microbial growth was categorized by microbial 
count greater than 1x105 cfu/ml. Microbial colonies were identified 
biochemically and serologically according to standard methods [19]. 
Isolates were speciated by routine procedures which included 
colonial characteristics, gram-staining, coagulase test and API 20 
system. Each colony, representing an isolate was emulsified in 2 ml 
sterile peptone water, and then transferred into sensitivity agar 




Susceptibility test was with the Kirby-Bauer disc diffusion method 
using sensitivity agar (Oxoid, UK) and pertinent antibiotics 
emphasizing ciprofloxacin with a break point of 5 μg. Inhibition zone 
diameters pertaining to ciprofloxacin were measured using calipers 
and compared with standard interpretation charts [20] and scored 




Data were checked for completeness, entered, and analyzed using 
SPSS version 20 (Armonk, NY: IBM Corp). Chi-square (χ²) was used 
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Ethical issues 
  






Out of the 705 urine samples analyzed, 374 (53%) were obtained 
from females whilst 331 (47%) were from males. Samples with 
significant microbial growth (>1x105 cfu/ml) constituted 112 
(15.9%), as shown in Table 1. Results also showed a higher 
incidence (p<0.0001) of UTI among females 84 (75%) than in male 
subjects 28 (25%). Predominant uropathogens isolated were E 
.coli 52 (46.4%) and Coliform 46 (41.1%). Other isolates found in 
this study; Pseudomonas spp., Salmonella spp., Candida spp., 
Klebsiella, and Coliform spp. with Candida are presented in Table 2. 
  
Table 3 shows the sensitivity pattern of microbial isolates to 
ciprofloxacin. E. coli, Coliform spp, and mixed Coliform + 
Candida spp. which together constitute 93.7% of total isolates 
showed sensitivities of 61.5%, 45.7% and 85% to ciprofloxacin 
respectively. Overall resistance among the top three isolated 
uropathogens to ciprofloxacin was 35.9%. The rest of the 
isolates; Pseudomonas spp., Salmonella spp., Candida spp. 
and Klebsiellawhich constituted 6.3 % of total isolates showed 





This study showed UTI prevalence rate of 15.9%, and its incidence 
was significantly higher in female than in males. Prevalence rate in 
this study was lower than findings of 31.6% from a study at the 
Ghana Police hospital in 2011 [17], and from a similar study in 
Ghana that reported 56.5% [4]. Multiple predisposing factors have 
been identified to contribute to higher prevalence among females. A 
major factor being anatomical differences in the urogenital organs 
between the two sexes; shorter urethra in females allows quicker 
access of bacteria to the urinary system [21]. Furthermore, poor 
personal hygiene coupled with certain cultural practices [22], may 
account for a higher incidence in women. On the other hand, the 
antibacterial activity of prostatic fluid in males makes them less 
susceptible to UTI [23]. Common bacteria isolated from cultures in 
studies conducted among UTI patients in Ghana include E. coli, 
Klebsiella, Candida and Salmonella spp [24, 25]. This study revealed 
that, E. coli and other coliform isolates constituted 87.2% of the 
total microbial isolates. Pseudomonas spp, Klebsiella spp, Candida 
spp and Salmonella spp are others identified among isolates with 
significant growth. These isolates are similar to those reported in 
studies done in Ghana [3, 4, 24,25] and elsewhere [2, 5]. 
Furthermore, in the current study the two most common isolated 
uropathogens are the same reported in an earlier study conducted 
at the Ghana Police Hospital, although their frequencies varied [17]. 
Also in the previous study,Staphylococcus aureus and 
Providencia were identified among uropathogens. 
  
Incidence of Candida spp (6.2%), and 
mixed Candida with Coliform (0.9%) in this study was higher than 
5.3% reported in a study conducted in Nigeria [26], and above the 
range (0.14-0.77%) from studies in Israel and Italy [27, 28]. 
Prevalence of yeast among isolates in the current study was lower 
than the 11% obtained from a similar study conducted in Kumasi, 
Ghana [25]. This finding suggests that, clinicians should consider 
treating possible underlying fungal infections especially when 
empirical treatment fails in recurrent UTIs. Due to the fact that 
resistance to antifungals among yeast has been linked to misuse 
and inappropriate prescription of antifungals [29], medical 
practitioners should only initiate empirical antifungal treatment 
when microbial susceptibility tests are unavailable. 
  
Fluoroquinolones are preferred in the treatment of UTI because 
they have a high bacteriologic and clinical cure rates, as well as low 
rates of resistance among most common uropathogens [30]. A 
review of susceptibility trends of uropathogens to ciprofloxacin in 
the 1990s showed high sensitivities of 93.9% for 
Enterobacteriaceae, 81.8% for P. aeruginosa 90.2% for gram 
positive aerobes [31], and 80% for gram-negative isolates [32]. The 
overall sensitivity (64.1%) of the top three isolated uropathogens to 
ciprofloxacin observed in this study was lower than findings from 
similar studies [31, 32]. Recently, ciprofloxacin resistant 
uropathogens have been reported in a number of countries. Those 
reported include 15 % in a study in Turkey [33], 15% in Gaza [12], 
14.7% in Spain [15], 33.3% in Nigeria [5], 28.6% in Iran [34], and 
rates of 46.6 to 59.4% in China [35]. Another study in South Africa 
revealed ciprofloxacin resistance of 11% for isolates from 
uncomplicated UTI and 41% for isolates from complicated UTI [36]. 
Additionally, the overall resistance (35.9%) of the top three 
uropathogens to ciprofloxacin in this study was relatively high 
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compared with other studies [5, 12, 33, 34]. Although the causative 
microorganisms of UTI keeps changing over the years, E. coli and 
Enterobacteriaceae remain the most common uropathogens, 
accounting for about 75-90% of laboratory culture isolates [2]. E. 
coli resistance to ciprofloxacin (38.5%) observed in this study, was 
lower than the 46.7% observed in a similar study in Ethiopia [37]. 
However, E. coli resistance to ciprofloxacin in this study was higher 
than similar studies; 32 % in Kumasi, Ghana [38], 11% from nine 
out of ten regions in Ghana [24], 33% in Ethiopia [39], and 22% in 
Switzerland [40]. 
  
In a related study that assessed fecal E. coli susceptibility to 
quinolones between the years 2006 and 2007, it was observed that 
13 (52%) of the isolates were resistant to ciprofloxacin, whilst in 
2008, 10 (67%) resistant [41]. Although the number of fecal E. 
coliisolates in these studies are fewer than that of isolated from 
urine, ciprofloxacin resistance among urine E. coli appears to be 
lower than those observed in fecal isolates. Since E. coli has been 
found to be the causative microorganism in over 70% of UTIs 
worldwide, its resistance to ciprofloxacin observed in this study, and 
other similar studies in Ghana should be of concern to medical 
practitioners and drug policy makers. Studies have shown that, 
pressure on drugs used in therapy can influence resistance pattern 
of causative organisms than intrinsic bacterial protective 
mechanisms [42]. In Ghana, the broad therapeutic indications of 
ciprofloxacin; typhoid fever, infectious diarrhoea, lower respiratory-
tract infections, gastro-enteritis, cholera, gonorrhea among others 
[43], exerts pressure on its use, and increases its risk of misuse. 
Additionally, although a prescription drug, ciprofloxacin can be 
obtained over the counter in a number of pharmacies in Ghana, and 





The relatively high ciprofloxacin resistance demonstrated by the 
most predominant isolates, Coliform spp. and E. coli, in this study 
should be of great concern to medical practitioners, drug regulatory 
agencies and policy makers. This emphasizes the need for 
continuous evaluation of the quality of common antibiotics, prudent 
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Table 2: Frequency and percent of microbial isolates with significant growth 
Isolate Frequency Percentage (%) 
E. coli 52 46.4 
Coliform spp. 46 41.1 
Coliform + Candida spp. 7 6.2 
Pseudomonas spp. 3 2.7 
Salmonella spp. 2 1.8 
Candida spp. 1 0.9 
Klebsiella spp. 1 0.9 
TOTAL 112 100 
 
 
Table 3: Sensitivity of isolates to ciprofloxacin 
Isolate Resistant (%) Sensitive (%) 
E. coli 38.5 61.5 
Coliform spp. 54.3 45.7 
Coliform + Candida spp. 15 85 
Pseudomonas spp. — 100 
Salmonella spp. — 100 
Candida spp. — 100 
Klebsiella spp. — 100 
 
 
Table 1: Level of microbial growth among UTI patients (n = 705) 
  Significant growth 
(>1x105 cfu/ml) 
No significant growth 
Number of urine cultures 112 593 
Percentage of urine cultures 15.9% 84.1% 
